TY  - JOUR
AU  - Kotecha, Rupesh
AU  - Akdemir, Eyub Y
AU  - Kutuk, Tugce
AU  - Ilgın, Can
AU  - Ahluwalia, Manmeet S
AU  - Bi, Wenya L
AU  - Blakeley, Jaishri
AU  - Dixit, Karan S
AU  - Dunn, Ian F
AU  - Galanis, Evanthia
AU  - Galldiks, Norbert
AU  - Huang, Raymond Y
AU  - Johnson, Derek R
AU  - Kaley, Thomas J
AU  - Kamson, David O
AU  - Kurz, Sylvia C
AU  - McDermott, Michael W
AU  - Odia, Yazmin
AU  - Preusser, Matthias
AU  - Raizer, Jeffrey
AU  - Reardon, David A
AU  - Rogers, C Leland
AU  - Ruda, Roberta
AU  - Schiff, David
AU  - Vogelbaum, Michael A
AU  - Weller, Michael
AU  - Wen, Patrick Y
AU  - Mehta, Minesh P
TI  - Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design
JO  - Neuro-Oncology
VL  - 27
IS  - 7
SN  - 1522-8517
CY  - Oxford
PB  - Oxford Univ. Press
M1  - FZJ-2026-00869
SP  - 1670 - 1685
PY  - 2025
N1  - Neuro Oncol . 2025 Sep 8;27(7):1670-1685.Funding: none declared
AB  - Background. Despite advances in our understanding of the molecular underpinnings of meningioma progressionand innovations in systemic and local treatments, recurrent meningiomas remain a substantial therapeutic challenge.The objective of this systematic review and meta-analysis is to provide a historical baseline, contemporaryanalysis, and propose a “rate of probable interest” to inform future clinical trial design and development on behalfof the Response Assessment in Neuro-Oncology meningioma group.Methods. PubMed, ClinicalTrials.gov, and ASCOpubs databases were screened for clinical trials evaluating theactivity of systemic therapies for adults with recurrent meningiomas. The pooled progression-free survival at6-months and 1-year (PFS-6 and PFS-1 year) values were calculated using the random effects technique withI2 indices.Results. The pooled PFS-6 and PFS-1 year rates for recurrent WHO grade 1 meningiomas were 43.6% (95% CI:22.7-67.0%, I2 = 80%) and 21.7% (95% CI: 6.2-53.9%, I2 = 76%), and for grades 2-3 meningiomas, the PFS-6 was 38.0%(95% CI: 28.3-48.8%, I2 = 68%). In the targeted therapy group, PFS-6 and PFS-1 year rates stood at 62.0% (I2 = 58%)and 49.0% (I2 = 63%) for grade 1, while for grades 2-3 tumors, the PFS-6 rates with targeted therapy and immunotherapywere 42.1% (I² = 60%) and 46.0% (I² = 0%), respectively. The benchmarks were set at 67% and 54% for PFS-6and PFS-1 year for grade 1 tumors, and PFS-6 of 49% for grades 2-3 tumors.Conclusions. Several studies have reported outcomes in patients with recurrent meningiomas testing a variety ofagents with modest, but variable and progressively increasing activity. In this context, we recommend new benchmarksfor future trials to define efficacy of future investigational therapies.
LB  - PUB:(DE-HGF)16
DO  - DOI:10.1093/neuonc/noaf009
UR  - https://juser.fz-juelich.de/record/1052252
ER  -